General Information of Drug Combination (ID: DCUNY8V)

Drug Combination Name
Acetohydroxamic Acid Triiodothyronine
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Acetohydroxamic Acid   DMYX7NI Triiodothyronine   DM14NKM
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 40.76
Bliss Independence Score: 40.76
Loewe Additivity Score: 57.31
LHighest Single Agent (HSA) Score: 57.32

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Acetohydroxamic Acid
Disease Entry ICD 11 Status REF
Urinary tract infection GC08 Approved [2]
Acetohydroxamic Acid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Urease (Bact ureC) TTAS2UO URE1_KLEAE Inhibitor [5]
------------------------------------------------------------------------------------
Acetohydroxamic Acid Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Decreases Activity [6]
------------------------------------------------------------------------------------
Indication(s) of Triiodothyronine
Disease Entry ICD 11 Status REF
Euthyroid goiter 5A01.1 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018749.
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076923.
4 ClinicalTrials.gov (NCT04348513) Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection. U.S. National Institutes of Health.
5 Enzymatic, immunological and phylogenetic characterization of Brucella suis urease. BMC Microbiol. 2008 Jul 19;8:121.
6 New bispyridinium oximes: in vitro and in vivo evaluation of their biological efficiency in soman and tabun poisoning. Chem Biol Interact. 2008 Sep 25;175(1-3):413-6.